Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Dose Escalation and Carmustine in Glioblastoma Multiforme
NCT00003417Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Sep 1998
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of carmustine in glioblastoma multiforme (GBM) (4 arms), sponsored by NRG Oncology. Primary endpoint: Dose-Limiting Toxicity at 90 days. Started Sep 1998; status: completed.
02
Drugs
carmustine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00003417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003417.